A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)

Completed · Phase 3

Conditions studied: Diabetes Mellitus, Type 2

In brief

This study looks at how a person with type 2 diabetes can be treated with insulin icodec and a flash glucose monitor (a small sensor inserted under the skin to measure blood sugar all the time). The study will look at how well insulin icodec controls blood sugar when used in combination with a flash glucose monitor. Participants will get insulin icodec that they have to inject once a week on the same day of the week. The insulin will be injected with a needle in a skin fold in the thigh, upper arm, or stomach. The study will last for about 8 months. Participants will have to wear a flash glucose monitor throughout the study. This is a sensor that fits on arm. Participants will be asked to use a commercially available app called LibreView to allow team to view flash glucose monitor data. Participants will get a study phone to scan the flash glucose monitor 4 times daily and they will be able to see all of the flash glucose monitor data during the study. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Key facts

Study ID: NCT05823948
Run by: Novo Nordisk A/S
People needed: 51
Starts: 2023-04-11
Expected to finish: 2024-04-11
Last updated by the study team: 2026-04-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
Age above or equal to 18 years at the time of signing informed consent
Diagnosed with type 2 diabetes (T2D) greater than or equal to (>=) 180 days before screening
HbA1c from 7.0%-11.0% (53.0-96.7 millimoles per mole [mmol/mol]) both inclusive at screening confirmed by central laboratory analysis
Insulin-naïve. However, short term insulin treatment for a maximum of 14 consecutive days before screening is allowed, as is prior insulin treatment for gestational diabetes
Stable daily dose(s) >=90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:
Any metformin formulations >= 1500 milligrams (mg) or maximum tolerated or effective dose or
Any metformin combination formulations >=1500 mg or maximum tolerated or effective dose or
Other antidiabetic Drugs including combination products (>=half of the maximum approved dose according to local label or maximum tolerated or effective dose) of the classes specified below: Sulfonylureas, Meglitinides (glinides), Dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors, Thiazolidinedione, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs, Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists
Intensification with basal insulin is indicated to achieve fasting glycaemic target (4.4-7.2 millimoles per liter [mmol/L]; 80-130 milligrams per deciliter [mg/dL]) at the discretion of the treating investigator
Body mass index (BMI) less than or equal to (<=) 40.0 kilograms per meter square (kg/m\^2)

You may not qualify if…

Unwilling or unable to avoid concomitant medication e.g., ascorbic acid (vitamin C) that can influence the flash glucose monitoring (FGM) sensor throughout the study and contraindications e.g., implanted medical devices such as pacemakers
Any episodes of diabetic ketoacidosis within 90 days before screening as declared by the participant or in the medical records
Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 180 days before the day of screening and between screening and initiation visits
Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening
Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g., treatment with orlistat, thyroid hormones, or corticosteroids)
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before the day of screening or in the period between screening and initiation visits. Pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Where it is running

Desert Oasis Hlthcr Med Group — Palm Springs, California, United States
Clinical Trials Research_Sacramento_0 — Sacramento, California, United States
San Diego Family Care — San Diego, California, United States
Mills-Peninsula Hlth Services — San Mateo, California, United States
Florida Inst For Clin Res LLC — Orlando, Florida, United States
Metabolic Research Institute Inc — West Palm Beach, Florida, United States
East West Med Res Inst — Honolulu, Hawaii, United States
Northern Pines Hlth Ctr, PC — Buckley, Michigan, United States
International Diabetes Center — Minneapolis, Minnesota, United States
Palm Research Center Inc-Vegas — Las Vegas, Nevada, United States
Accellacare_NC — Wilmington, North Carolina, United States
Diabetes & Endocrinology Asso — Canton, Ohio, United States
AM Diabetes And Endocrinology — Bartlett, Tennessee, United States
Amarillo Medical Specialists — Amarillo, Texas, United States
Velocity Clin Res, Dallas — Dallas, Texas, United States
UT Southwestern Med Cntr — Dallas, Texas, United States
Fmc Science, Llc — Lampasas, Texas, United States
Clinical Trials of Texas Inc — San Antonio, Texas, United States
Northeast Clinical Research of San Antonio — San Antonio, Texas, United States
Chrysalis Clinical Research — St. George, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.